Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis

Next Previous
Search
Trial Profile

A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesalazine/acetylcysteine (Primary) ; Mesalazine
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Altheus Therapeutics

    • Most Recent Events

    • 28 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
    • 09 Jan 2014 Topline results are expected in to be available in March or early April 2014, according to an Altheus Therapeutics media release.
    • 07 Jan 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top